中国现代医学杂志2026，Vol.36Issue(4)：13-18,6.DOI:10.3969/j.issn.1005-8982.2026.04.003
血清EGFR、E-cadherin预测乳腺癌新辅助化疗疗效的价值
Value of serum EGFR and E-cadherin as predictive indicators for therapeutic efficacy of neoadjuvant chemotherapy in breast cancer
摘要
Abstract
Objective To analyze the predictive value of serum epidermal growth factor receptor(EGFR)and E-cadherin in predicting treatment response to neoadjuvant chemotherapy for breast cancer.Methods A total of 151 breast cancer patients admitted to the Third People's Hospital of Mianyang City from January 2020 to March 2023 undergoing neoadjuvant chemotherapy were included.Multivariable stepwise logistic regression was used to analyze the influencing factors,and the receiver operating characteristic(ROC)curve was used to verify the diagnostic efficacy.Results The proportion of stage Ⅱ tumors and the level of E-cadherin in the pCR group were higher than those in the non-pCR group,while the proportion of KI-67 antigen expression≥30％and the levels of CEA and EGFR were lower in the pCR group than in the non-pCR group.Multivariable stepwise logistic regression analysis showed that stage Ⅲ tumors[(OR)=4.899(95％CI:2.016,11.909)],high EGFR levels[(OR)=3.904(95％CI:1.594,9.563)],and low E-cadherin levels[(OR)=0.308(95％CI:0.127,0.748)]were all risk factors for incomplete response to neoadjuvant chemotherapy in breast cancer patients(P<0.05).ROC curve analysis revealed that the sensitivities of EGFR,E-cadherin,and the combined model for predicting incomplete response to neoadjuvant chemotherapy were 69.44％(95％CI:0.517,0.831),72.2％(95％CI:0.546,0.852),and 83.33％(95％CI:0.665,0.930),respectively,with corresponding specificities being 75.65％(95％CI:0.666,0.830),70.43％(95％CI:0.611,0.784),and 88.69％(95％CI:0.811,0.936),respectively,and the areas under the curves being 0.722(95％CI:0.609,0.834),0.726(95％CI:0.629,0.822),and 0.896(95％CI:0.826,0.966),respectively.Conclusion Combined detection of serum EGFR and E-cadherin can improve the predictive performance for the efficacy of neoadjuvant chemotherapy in breast cancer.关键词
乳腺癌/新辅助化疗/表皮生长因子受体/E-钙黏连蛋白/疗效Key words
breast cancer/neoadjuvant chemotherapy/epidermal growth factor receptor/E-cadherin/curative effect分类
医药卫生引用本文复制引用
龚土平,杜婷,吴雪莲,李霞,卜亮..血清EGFR、E-cadherin预测乳腺癌新辅助化疗疗效的价值[J].中国现代医学杂志,2026,36(4):13-18,6.基金项目
四川省科技厅科技计划项目(No:2022YFQ0003) （No:2022YFQ0003）
